Title:
BISPECIFIC ANTIBODY TARGETING SIRPα AND PD-L1 OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE
Document Type and Number:
WIPO Patent Application WO/2023/231705
Kind Code:
A1
Abstract:
A bispecific antibody targeting SIRPα and PD-L1 or an antigen-binding fragment thereof and a use. The bispecific antibody comprises an SIRPα binding domain and a PD-L1 binding domain; the SIRPα binding domain comprises a heavy chain variable region and a light chain variable region, and the PD-L1 binding domain comprises: a VHH fragment. Also provided are a drug comprising the bispecific antibody targeting SIRPα and PD-L1 or the antigen-binding fragment thereof, a nucleic acid molecule, a vector, a host cell obtained by conversion of the vector, and a pharmaceutical use of the antibody.
Inventors:
QU XIANGDONG (CN)
PAN QIN (CN)
DU YEJIE (CN)
PAN QIN (CN)
DU YEJIE (CN)
Application Number:
PCT/CN2023/092580
Publication Date:
December 07, 2023
Filing Date:
May 06, 2023
Export Citation:
Assignee:
QURE BIOTECHNOLOGY SHANGHAI CO LTD (CN)
International Classes:
C07K16/28; A61K39/395; A61P31/00; A61P35/00; A61P37/00; C07K19/00
Foreign References:
| CN111635458A | 2020-09-08 | |||
| CN114040925A | 2022-02-11 | |||
| CN112574309A | 2021-03-30 | |||
| CN112142842A | 2020-12-29 | |||
| CN113637082A | 2021-11-12 | |||
| CN110650976A | 2020-01-03 | |||
| US20210163599A1 | 2021-06-03 |
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF: